Estonia - estoński - Ravimiamet

g.l. pharma gmbh - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+25mg 28tk; 100mg+25mg 280tk; 100mg+25mg 7tk; 100mg+25mg 100tk; 100mg+25mg 10tk

Estonia - estoński - Ravimiamet

g.l. pharma gmbh - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 50mg+12,5mg 50tk; 50mg+12,5mg 56tk; 50mg+12,5mg 30tk; 50mg+12,5mg 14tk; 50mg+12,5mg 100tk; 50mg+12,5mg 280tk; 50mg+12,5mg 28tk; 50mg+12,5mg 10tk

Estonia - estoński - Ravimiamet

g.l. pharma gmbh - losartaan - õhukese polümeerikattega tablett - 100mg 21tk; 100mg 7tk; 100mg 100tk; 100mg 98tk; 100mg 280tk; 100mg 15tk; 100mg 28tk; 100mg 50tk

Estonia - estoński - Ravimiamet

g.l. pharma gmbh - losartaan - õhukese polümeerikattega tablett - 50mg 7tk; 50mg 280tk; 50mg 28tk; 50mg 30tk; 50mg 21tk; 50mg 15tk; 50mg 56tk; 50mg 14tk

Estonia - estoński - Ravimiamet

laboratorios liconsa s.a. - losartaan - õhukese polümeerikattega tablett - 50mg 10tk; 50mg 7tk; 50mg 21tk; 50mg 105tk; 50mg 210tk

Estonia - estoński - Ravimiamet

laboratorios liconsa s.a. - losartaan - õhukese polümeerikattega tablett - 12,5mg 7tk; 12,5mg 105tk; 12,5mg 21tk; 12,5mg 100tk; 12,5mg 112tk; 12,5mg 14tk; 12,5mg 110tk; 12,5mg 280tk

Estonia - estoński - Ravimiamet

laboratorios liconsa s.a. - losartaan - õhukese polümeerikattega tablett - 100mg 28tk; 100mg 7tk; 100mg 105tk; 100mg 110tk; 100mg 210tk; 100mg 21tk; 100mg 14tk; 100mg 100tk; 100mg 98tk; 100mg 280tk; 100mg 112tk; 100mg 50tk; 100mg 56tk

Unia Europejska - estoński - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - eesnäärmevähk - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Unia Europejska - estoński - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionukliidi pildistamine - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Unia Europejska - estoński - EMA (European Medicines Agency)

blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. axumin on näidustatud positronemissioontomograafia (pet) pildindus avastada kordumise eesnäärmevähi täiskasvanud mehed, kellel kahtlustatakse kordumise põhineb vere kõrgenenud eesnäärmevähi spetsiifilise antigeeni (psa) taseme pärast esmast tervendavat ravi.